Washington Vaccine Alliance


To develop an integrated, multi-institutional program to stimulate discovery and development of vaccines for widespread use

Anticipated Impact: 

New vaccines to prevent or treat herpes, syphilis, and E. coli contamination of beef


Scientific and financial constraints throughout the vaccine development process result in delays and high product costs that limit the public health impact of candidate vaccines. Because of these challenges, the firms that develop vaccines do so only when validated animal tests or human clinical trials demonstrate a likelihood of success. The Washington Vaccine Alliance will bring a shared translational research framework and interdisciplinary expertise to vaccine economics, design, formulation, testing, materials production, immune response assessment, and product planning.

Three specific vaccine projects will be initially addressed. One in five adults in Washington State is infected with the herpes simplex virus (HSV)-2. Infectious syphilis cases have doubled in the United States since 2000 and E. coli contamination continues to be a persistent problem in the nation's food sources. Each of these disease agents costs Washington and the nation billions of dollars in treatment and care.

Collaborating organizations: Battelle, Pacific Northwest Division; Infectious Disease Research Institute, Program for Appropriate Technology in Health, Seattle Biomedical Research Institute, University of Washington, Washington State University

See also:

2010 LSDF/WBBA Open House Poster
LSDF Board Meeting Presentation (December 7, 2010)

E. coli Vaccine
Herpes Vaccine
Syphilis Vaccine

Grant Update

Principal Investigator:
Lawrence Corey
Grantee Organization:
Fred Hutchinson Cancer Research Center
Grant Title:
Washington Vaccine Alliance
Grant Cohort and Year:
2008 Innovative Programs to Advance Health Research (02)
Grant Period:
06/15/2009 - 06/14/2014 (Completed)
Grant Amount:
Earlier during this reporting period, the decision was made to wind down WAVA activities and expedite completion of ongoing projects. Only the Syphilis and Salmonella Projects were active during the period of this report. E. Coli, Typhoid and HSV Projects were not active during this period. Core functions were limited to coordination with LSDF and project sites regarding continuation of the two ongoing projects. Project Outcomes: Syphilis Project - Although there was substantial difference in the efficacy of different adjuvants tested in potential vaccines, even the best adjuvant and antigen cocktail identified in our studies were not able to induce complete protection against syphilis infection. Nonetheless, we learned much about the adjuvant components that are most important for immunity against syphilis, and this information will be used in future vaccine studies that continue in the laboratory. Salmonella Project - The salmonella pilot project seeks to identify virulence associated genes of Salmonella Enteritidis, a major food-borne pathogen responsible for food-borne gastroenteritis throughout the world. The major source of this pathogen is poultry derived food and therefore the long term objective of this project is to develop rationally attenuated mutants of S. Enteritidis that could become targets for the development of a live vaccine for use in poultry. The project is ongoing and is sequencing genes of mutant Salmonella bacteria in order to identify genes potentially associated with intestinal colonization of the bacteria in chickens. Once identified these mutants will aid in construction of a chicken infection model in order to test potential vaccines.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
8, 9, 11, 34, 36, 37, 43, 46

Health Impacts

E. coli Vaccine
Herpes Vaccine
Syphilis Vaccine